Xspray Pharma Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Xspray Pharma de 134.8% y 134.5% respectivamente, mientras que el BPA crecerá en un 126.8% al año.

Información clave

134.8%

Tasa de crecimiento de los beneficios

126.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	46.0%
Tasa de crecimiento de los ingresos	134.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OM:XSPRAY - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,618	818	N/A	N/A	2
12/31/2025	498	-60	-154	-60	2
12/31/2024	5	-216	-283	-198	1
9/30/2024	N/A	-258	-232	-193	N/A
6/30/2024	N/A	-215	-259	-221	N/A
3/31/2024	N/A	-213	-257	-213	N/A
12/31/2023	N/A	-180	-256	-203	N/A
9/30/2023	N/A	-180	-268	-206	N/A
6/30/2023	N/A	-170	-242	-160	N/A
3/31/2023	N/A	-148	-223	-128	N/A
12/31/2022	N/A	-132	-238	-110	N/A
9/30/2022	N/A	-128	-216	-85	N/A
6/30/2022	N/A	-114	-198	-79	N/A
3/31/2022	N/A	-102	-185	-67	N/A
12/31/2021	N/A	-97	-148	-52	N/A
9/30/2021	N/A	-60	-146	-53	N/A
6/30/2021	N/A	-57	-145	-49	N/A
3/31/2021	N/A	-56	-141	-46	N/A
12/31/2020	N/A	-52	-141	-48	N/A
9/30/2020	N/A	-56	-141	-48	N/A
6/30/2020	N/A	-55	-140	-44	N/A
3/31/2020	N/A	-49	-135	-35	N/A
12/31/2019	N/A	-46	-126	-34	N/A
9/30/2019	-22	-41	-115	-29	N/A
6/30/2019	-14	-34	-97	-24	N/A
3/31/2019	-6	-30	-91	-27	N/A
12/31/2018	0	-23	-65	-18	N/A
9/30/2018	31	-17	-62	-25	N/A
6/30/2018	28	-16	N/A	-12	N/A
3/31/2018	29	-8	N/A	-7	N/A
12/31/2017	0	-14	N/A	-12	N/A
9/30/2017	35	1	N/A	12	N/A
6/30/2017	30	-3	N/A	-2	N/A
3/31/2017	21	-7	N/A	-6	N/A
12/31/2016	21	-4	N/A	-2	N/A
12/31/2015	5	-12	N/A	-13	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que XSPRAY sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1.2%).

Beneficios vs. Mercado: Se prevé que XSPRAY sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que XSPRAY sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (134.5% al año) de XSPRAY crezcan más rápidamente que los del mercado Swedish (0.09% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (134.5% al año) de XSPRAY crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de XSPRAY se prevé que sea elevada dentro de 3 años.

Xspray Pharma Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 24% to kr91.50

Price target decreased by 11% to kr107

Price target decreased by 21% to kr106

Forecast to breakeven in 2024

Price target decreased to kr116

Forecast to breakeven in 2024

Recent updates

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million.

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

New major risk - Financial position

Director recently bought kr4.8m worth of stock

Price target decreased by 24% to kr91.50

New major risk - Share price stability

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Director recently bought kr143k worth of stock

Now 32% undervalued

Now 23% undervalued

Price target decreased by 11% to kr107

New minor risk - Share price stability

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Director recently bought kr504k worth of stock

Chief Executive Officer recently sold kr75k worth of stock

Chairman exercised options to buy kr24m worth of stock.

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

New minor risk - Share price stability

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Xspray Pharma AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

New major risk - Revenue and earnings growth

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (publ) Appoints Kerstin Hasselgren as Head of IR

Director recently bought kr2.1m worth of stock

Independent Director exercised options to buy kr97k worth of stock.

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Price target decreased by 21% to kr106

Chief Executive Officer recently sold kr2.2m worth of stock

Director recently bought kr135k worth of stock

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 29, 2023

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Price target decreased to kr116

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Price target decreased to kr116

No longer forecast to breakeven

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Independent Chairman of the Board Michael Jensen has left the company

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

New 90-day low: kr113

Xspray Pharma AB (publ) Announces Nomination Committee for the AGM 2021

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

New 90-day low: kr114

Chief Executive Officer exercised options and sold kr3.6m worth of stock

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

New 90-day low: kr127